OMEGA THERAPEUTICS INC (OMGA) Forecast, Price Target & Analyst Ratings
NASDAQ:OMGA • US68217N1054
0.1426 USD
-0.02 (-10.82%)
At close: Feb 24, 2025
0.11 USD
-0.03 (-22.86%)
After Hours: 2/24/2025, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OMEGA THERAPEUTICS INC (OMGA).
Forecast Snapshot
Consensus Price Target
$13.26
+ 9,198.74% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ4 / 2024
EPS Estimate-$0.21
Revenue Estimate1.456M
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.26
Upside
+ 9,198.74%
From current price of $0.14 to mean target of $13.26, Based on 7 analyst forecasts
Low
$11.11
Median
$13.26
High
$15.75
Price Target Revisions
1 Month
40.54%
3 Months
40.54%
Price Target Summary
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
The average price target has been revised upward by 40.54% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
OMGA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about OMGA.
In the previous month the buy percentage consensus was at a similar level.
OMGA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-07 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-06-18 | Raymond James | Initiate | Outperform |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-01-04 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-31 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | JonesTrading | Initiate | Buy |
| 2023-03-03 | Piper Sandler | Maintains | Overweight |
| 2022-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-23 | Chardan Capital | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ4 / 2024
EPS Estimate-$0.21
Revenue Estimate1.456M
Revenue Q2Q47.22%
EPS Q2Q43.49%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-4.71%
EPS (1 Month)
0.00%
EPS (3 Months)
15.75%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 4.71% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.07M | 3.094M 49.47% | 8.706M 181.38% | 4.394M -49.53% | 6.747M 53.55% | 34.053M 404.71% | 259.91M 663.25% | 527.63M 103.00% | 885.1M 67.75% | 27.617M -96.88% | 16.001M -42.06% | ||
| EBITDA YoY % growth | -64.79M -135.60% | -101.21M -56.21% | -98.693M 2.49% | -61.49M 37.70% | -60.792M 1.13% | -87.822M -44.46% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -66.18M -130.99% | -102.77M -55.29% | -100.261M 2.44% | -66.505M 33.67% | -45.513M 31.56% | -26.244M 42.34% | -66.52M -153.47% | 113.08M 269.99% | 300.14M 165.42% | 554.15M 84.63% | 9.402M -98.30% | -2.675M -128.46% | |
| Operating Margin | N/A | -4,964.73% | -3,240.50% | -763.89% | -1,035.81% | -388.97% | -195.34% | 43.51% | 56.88% | 62.61% | 34.04% | -16.72% | |
| EPS YoY % growth | N/A | -2.14 18.13% | -1.81 15.42% | -1.19 34.35% | -0.80 32.62% | -0.45 43.95% | -0.77 -70.45% | 1.60 309.33% | 3.88 142.04% | 6.10 57.37% | 0.97 -84.11% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 43.49% | -0.18 50.42% | -0.20 33.70% | -0.20 32.00% | -0.22 -7.32% |
| Revenue Q2Q % growth | 1.456M 47.22% | 1.099M -53.43% | 1.099M -48.50% | 1.099M -57.92% | 1.099M -24.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.984M 42.10% | -10.093M 50.65% | -11.035M 33.44% | -11.719M 28.63% | -12.666M -5.69% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.55%
EPS Next 5 Year
23.60%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
37.19%
Revenue Next 5 Year
150.92%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
6.19%
EBIT Next 5 Year
N/A
OMEGA THERAPEUTICS INC / OMGA Forecast FAQ
What is the average price target for OMEGA THERAPEUTICS INC (OMGA) stock?
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
What are the consensus estimates for OMGA stock next earnings?
The consensus EPS estimate for the next earnings of OMEGA THERAPEUTICS INC (OMGA) is -0.21 USD and the consensus revenue estimate is 1.46M USD.
What is the expected long term growth rate for OMGA stock?
The expected long term growth rate for OMEGA THERAPEUTICS INC (OMGA) is 37.19%.